nodes	percent_of_prediction	percent_of_DWPC	metapath
Maraviroc—CYP3A4—Cytarabine—lymphatic system cancer	0.115	0.318	CbGbCtD
Maraviroc—CYP3A4—Teniposide—lymphatic system cancer	0.113	0.313	CbGbCtD
Maraviroc—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0792	0.219	CbGbCtD
Maraviroc—CYP3A4—Vincristine—lymphatic system cancer	0.0545	0.151	CbGbCtD
Maraviroc—Depression—Vincristine—lymphatic system cancer	0.00136	0.00213	CcSEcCtD
Maraviroc—Anorexia—Fludarabine—lymphatic system cancer	0.00136	0.00213	CcSEcCtD
Maraviroc—Proteinuria—Methotrexate—lymphatic system cancer	0.00135	0.00211	CcSEcCtD
Maraviroc—Acute coronary syndrome—Vincristine—lymphatic system cancer	0.00135	0.00211	CcSEcCtD
Maraviroc—Myocardial infarction—Vincristine—lymphatic system cancer	0.00134	0.0021	CcSEcCtD
Maraviroc—Neuropathy peripheral—Vincristine—lymphatic system cancer	0.00134	0.0021	CcSEcCtD
Maraviroc—Pneumonia—Mitoxantrone—lymphatic system cancer	0.00134	0.0021	CcSEcCtD
Maraviroc—Stomatitis—Vincristine—lymphatic system cancer	0.00133	0.00209	CcSEcCtD
Maraviroc—Protein urine present—Methotrexate—lymphatic system cancer	0.00133	0.00208	CcSEcCtD
Maraviroc—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00133	0.00208	CcSEcCtD
Maraviroc—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	0.00131	0.00205	CcSEcCtD
Maraviroc—Renal failure—Mitoxantrone—lymphatic system cancer	0.00131	0.00205	CcSEcCtD
Maraviroc—Nausea—Mechlorethamine—lymphatic system cancer	0.00131	0.00205	CcSEcCtD
Maraviroc—Myocardial infarction—Mitoxantrone—lymphatic system cancer	0.0013	0.00204	CcSEcCtD
Maraviroc—Hyperbilirubinaemia—Methotrexate—lymphatic system cancer	0.0013	0.00204	CcSEcCtD
Maraviroc—Alopecia—Bleomycin—lymphatic system cancer	0.0013	0.00204	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.0013	0.00203	CcSEcCtD
Maraviroc—Stomatitis—Mitoxantrone—lymphatic system cancer	0.0013	0.00203	CcSEcCtD
Maraviroc—Jaundice—Mitoxantrone—lymphatic system cancer	0.0013	0.00203	CcSEcCtD
Maraviroc—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00129	0.00203	CcSEcCtD
Maraviroc—Oliguria—Methotrexate—lymphatic system cancer	0.00128	0.00201	CcSEcCtD
Maraviroc—Herpes simplex—Methotrexate—lymphatic system cancer	0.00128	0.00201	CcSEcCtD
Maraviroc—Abdominal pain—Teniposide—lymphatic system cancer	0.00128	0.00201	CcSEcCtD
Maraviroc—Body temperature increased—Teniposide—lymphatic system cancer	0.00128	0.00201	CcSEcCtD
Maraviroc—Erythema—Bleomycin—lymphatic system cancer	0.00128	0.00201	CcSEcCtD
Maraviroc—Paraesthesia—Fludarabine—lymphatic system cancer	0.00128	0.00201	CcSEcCtD
Maraviroc—Hallucination—Carmustine—lymphatic system cancer	0.00128	0.002	CcSEcCtD
Maraviroc—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00126	0.00198	CcSEcCtD
Maraviroc—Ulcer—Methotrexate—lymphatic system cancer	0.00125	0.00196	CcSEcCtD
Maraviroc—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00125	0.00195	CcSEcCtD
Maraviroc—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00124	0.00194	CcSEcCtD
Maraviroc—Decreased appetite—Fludarabine—lymphatic system cancer	0.00124	0.00194	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00123	0.00193	CcSEcCtD
Maraviroc—Fatigue—Fludarabine—lymphatic system cancer	0.00123	0.00193	CcSEcCtD
Maraviroc—Inflammation—Methotrexate—lymphatic system cancer	0.00122	0.00191	CcSEcCtD
Maraviroc—Hallucination—Vincristine—lymphatic system cancer	0.00122	0.00191	CcSEcCtD
Maraviroc—Pain—Fludarabine—lymphatic system cancer	0.00122	0.00191	CcSEcCtD
Maraviroc—Constipation—Fludarabine—lymphatic system cancer	0.00122	0.00191	CcSEcCtD
Maraviroc—Vasculitis—Methotrexate—lymphatic system cancer	0.00121	0.0019	CcSEcCtD
Maraviroc—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00121	0.0019	CcSEcCtD
Maraviroc—Respiratory failure—Methotrexate—lymphatic system cancer	0.00121	0.00189	CcSEcCtD
Maraviroc—Connective tissue disorder—Vincristine—lymphatic system cancer	0.0012	0.00189	CcSEcCtD
Maraviroc—Urethral disorder—Vincristine—lymphatic system cancer	0.0012	0.00188	CcSEcCtD
Maraviroc—Eye disorder—Carmustine—lymphatic system cancer	0.0012	0.00188	CcSEcCtD
Maraviroc—Rhinitis—Mitoxantrone—lymphatic system cancer	0.0012	0.00187	CcSEcCtD
Maraviroc—Hypersensitivity—Teniposide—lymphatic system cancer	0.00119	0.00187	CcSEcCtD
Maraviroc—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00118	0.00186	CcSEcCtD
Maraviroc—Anaemia—Bleomycin—lymphatic system cancer	0.00118	0.00185	CcSEcCtD
Maraviroc—Asthenia—Teniposide—lymphatic system cancer	0.00116	0.00182	CcSEcCtD
Maraviroc—Pruritus—Teniposide—lymphatic system cancer	0.00115	0.0018	CcSEcCtD
Maraviroc—Leukopenia—Bleomycin—lymphatic system cancer	0.00115	0.0018	CcSEcCtD
Maraviroc—Cardiac disorder—Vincristine—lymphatic system cancer	0.00114	0.00178	CcSEcCtD
Maraviroc—Alopecia—Carmustine—lymphatic system cancer	0.00113	0.00178	CcSEcCtD
Maraviroc—Body temperature increased—Fludarabine—lymphatic system cancer	0.00113	0.00177	CcSEcCtD
Maraviroc—Mental disorder—Carmustine—lymphatic system cancer	0.00112	0.00176	CcSEcCtD
Maraviroc—Malnutrition—Carmustine—lymphatic system cancer	0.00112	0.00175	CcSEcCtD
Maraviroc—Erythema—Carmustine—lymphatic system cancer	0.00112	0.00175	CcSEcCtD
Maraviroc—Cough—Bleomycin—lymphatic system cancer	0.00112	0.00175	CcSEcCtD
Maraviroc—Angiopathy—Vincristine—lymphatic system cancer	0.00111	0.00174	CcSEcCtD
Maraviroc—Diarrhoea—Teniposide—lymphatic system cancer	0.00111	0.00174	CcSEcCtD
Maraviroc—Mediastinal disorder—Vincristine—lymphatic system cancer	0.0011	0.00173	CcSEcCtD
Maraviroc—Myalgia—Bleomycin—lymphatic system cancer	0.00109	0.00171	CcSEcCtD
Maraviroc—Alopecia—Vincristine—lymphatic system cancer	0.00108	0.0017	CcSEcCtD
Maraviroc—Discomfort—Bleomycin—lymphatic system cancer	0.00108	0.00169	CcSEcCtD
Maraviroc—Mental disorder—Vincristine—lymphatic system cancer	0.00107	0.00168	CcSEcCtD
Maraviroc—Neoplasm—Methotrexate—lymphatic system cancer	0.00107	0.00168	CcSEcCtD
Maraviroc—Urine output increased—Methotrexate—lymphatic system cancer	0.00107	0.00168	CcSEcCtD
Maraviroc—Alopecia—Mitoxantrone—lymphatic system cancer	0.00105	0.00165	CcSEcCtD
Maraviroc—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00105	0.00165	CcSEcCtD
Maraviroc—Tremor—Carmustine—lymphatic system cancer	0.00105	0.00164	CcSEcCtD
Maraviroc—Oedema—Bleomycin—lymphatic system cancer	0.00104	0.00164	CcSEcCtD
Maraviroc—Erythema—Mitoxantrone—lymphatic system cancer	0.00104	0.00163	CcSEcCtD
Maraviroc—Infection—Bleomycin—lymphatic system cancer	0.00104	0.00163	CcSEcCtD
Maraviroc—Anaemia—Carmustine—lymphatic system cancer	0.00103	0.00162	CcSEcCtD
Maraviroc—Vomiting—Teniposide—lymphatic system cancer	0.00103	0.00162	CcSEcCtD
Maraviroc—Asthenia—Fludarabine—lymphatic system cancer	0.00102	0.0016	CcSEcCtD
Maraviroc—Rash—Teniposide—lymphatic system cancer	0.00102	0.0016	CcSEcCtD
Maraviroc—Dermatitis—Teniposide—lymphatic system cancer	0.00102	0.0016	CcSEcCtD
Maraviroc—Headache—Teniposide—lymphatic system cancer	0.00102	0.00159	CcSEcCtD
Maraviroc—Pruritus—Fludarabine—lymphatic system cancer	0.00101	0.00158	CcSEcCtD
Maraviroc—Lymphadenopathy—Methotrexate—lymphatic system cancer	0.00101	0.00158	CcSEcCtD
Maraviroc—Leukopenia—Carmustine—lymphatic system cancer	0.001	0.00157	CcSEcCtD
Maraviroc—Anorexia—Bleomycin—lymphatic system cancer	0.000996	0.00156	CcSEcCtD
Maraviroc—Diabetes mellitus—Methotrexate—lymphatic system cancer	0.000988	0.00155	CcSEcCtD
Maraviroc—Anaemia—Vincristine—lymphatic system cancer	0.000986	0.00155	CcSEcCtD
Maraviroc—Polyuria—Methotrexate—lymphatic system cancer	0.000979	0.00153	CcSEcCtD
Maraviroc—Diarrhoea—Fludarabine—lymphatic system cancer	0.000975	0.00153	CcSEcCtD
Maraviroc—Convulsion—Carmustine—lymphatic system cancer	0.000968	0.00152	CcSEcCtD
Maraviroc—Nausea—Teniposide—lymphatic system cancer	0.000963	0.00151	CcSEcCtD
Maraviroc—Anaemia—Mitoxantrone—lymphatic system cancer	0.00096	0.0015	CcSEcCtD
Maraviroc—Hepatic failure—Methotrexate—lymphatic system cancer	0.000956	0.0015	CcSEcCtD
Maraviroc—Leukopenia—Vincristine—lymphatic system cancer	0.000955	0.0015	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.000952	0.00149	CcSEcCtD
Maraviroc—Myalgia—Carmustine—lymphatic system cancer	0.000951	0.00149	CcSEcCtD
Maraviroc—Anxiety—Carmustine—lymphatic system cancer	0.000948	0.00149	CcSEcCtD
Maraviroc—Paraesthesia—Bleomycin—lymphatic system cancer	0.000938	0.00147	CcSEcCtD
Maraviroc—Renal failure acute—Methotrexate—lymphatic system cancer	0.000931	0.00146	CcSEcCtD
Maraviroc—Leukopenia—Mitoxantrone—lymphatic system cancer	0.00093	0.00146	CcSEcCtD
Maraviroc—Convulsion—Vincristine—lymphatic system cancer	0.000924	0.00145	CcSEcCtD
Maraviroc—Oedema—Carmustine—lymphatic system cancer	0.000912	0.00143	CcSEcCtD
Maraviroc—Dermatitis exfoliative—Methotrexate—lymphatic system cancer	0.000911	0.00143	CcSEcCtD
Maraviroc—Decreased appetite—Bleomycin—lymphatic system cancer	0.000908	0.00142	CcSEcCtD
Maraviroc—Myalgia—Vincristine—lymphatic system cancer	0.000908	0.00142	CcSEcCtD
Maraviroc—Cough—Mitoxantrone—lymphatic system cancer	0.000907	0.00142	CcSEcCtD
Maraviroc—Infection—Carmustine—lymphatic system cancer	0.000906	0.00142	CcSEcCtD
Maraviroc—Vomiting—Fludarabine—lymphatic system cancer	0.000906	0.00142	CcSEcCtD
Maraviroc—Convulsion—Mitoxantrone—lymphatic system cancer	0.0009	0.00141	CcSEcCtD
Maraviroc—Rash—Fludarabine—lymphatic system cancer	0.000899	0.00141	CcSEcCtD
Maraviroc—Dermatitis—Fludarabine—lymphatic system cancer	0.000898	0.00141	CcSEcCtD
Maraviroc—Pain—Bleomycin—lymphatic system cancer	0.000893	0.0014	CcSEcCtD
Maraviroc—Headache—Fludarabine—lymphatic system cancer	0.000893	0.0014	CcSEcCtD
Maraviroc—Myalgia—Mitoxantrone—lymphatic system cancer	0.000884	0.00139	CcSEcCtD
Maraviroc—Anxiety—Mitoxantrone—lymphatic system cancer	0.000881	0.00138	CcSEcCtD
Maraviroc—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.000877	0.00137	CcSEcCtD
Maraviroc—Discomfort—Mitoxantrone—lymphatic system cancer	0.000874	0.00137	CcSEcCtD
Maraviroc—Oedema—Vincristine—lymphatic system cancer	0.000871	0.00136	CcSEcCtD
Maraviroc—Anorexia—Carmustine—lymphatic system cancer	0.000869	0.00136	CcSEcCtD
Maraviroc—Infection—Vincristine—lymphatic system cancer	0.000865	0.00136	CcSEcCtD
Maraviroc—Nervous system disorder—Vincristine—lymphatic system cancer	0.000854	0.00134	CcSEcCtD
Maraviroc—Oedema—Mitoxantrone—lymphatic system cancer	0.000848	0.00133	CcSEcCtD
Maraviroc—Nausea—Fludarabine—lymphatic system cancer	0.000846	0.00133	CcSEcCtD
Maraviroc—Infection—Mitoxantrone—lymphatic system cancer	0.000842	0.00132	CcSEcCtD
Maraviroc—Shock—Mitoxantrone—lymphatic system cancer	0.000834	0.00131	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.000831	0.0013	CcSEcCtD
Maraviroc—Anorexia—Vincristine—lymphatic system cancer	0.00083	0.0013	CcSEcCtD
Maraviroc—Body temperature increased—Bleomycin—lymphatic system cancer	0.000826	0.00129	CcSEcCtD
Maraviroc—Insomnia—Carmustine—lymphatic system cancer	0.000825	0.00129	CcSEcCtD
Maraviroc—Skin disorder—Mitoxantrone—lymphatic system cancer	0.000824	0.00129	CcSEcCtD
Maraviroc—Paraesthesia—Carmustine—lymphatic system cancer	0.000819	0.00128	CcSEcCtD
Maraviroc—Anorexia—Mitoxantrone—lymphatic system cancer	0.000808	0.00127	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.000793	0.00124	CcSEcCtD
Maraviroc—Decreased appetite—Carmustine—lymphatic system cancer	0.000793	0.00124	CcSEcCtD
Maraviroc—Insomnia—Vincristine—lymphatic system cancer	0.000787	0.00123	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.000787	0.00123	CcSEcCtD
Maraviroc—Paraesthesia—Vincristine—lymphatic system cancer	0.000782	0.00123	CcSEcCtD
Maraviroc—Constipation—Carmustine—lymphatic system cancer	0.00078	0.00122	CcSEcCtD
Maraviroc—Pain—Carmustine—lymphatic system cancer	0.00078	0.00122	CcSEcCtD
Maraviroc—Breast disorder—Methotrexate—lymphatic system cancer	0.000777	0.00122	CcSEcCtD
Maraviroc—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	0.000774	0.00121	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.000772	0.00121	CcSEcCtD
Maraviroc—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00077	0.00121	CcSEcCtD
Maraviroc—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.000761	0.00119	CcSEcCtD
Maraviroc—Decreased appetite—Vincristine—lymphatic system cancer	0.000757	0.00119	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.000752	0.00118	CcSEcCtD
Maraviroc—Fatigue—Vincristine—lymphatic system cancer	0.000751	0.00118	CcSEcCtD
Maraviroc—Asthenia—Bleomycin—lymphatic system cancer	0.00075	0.00117	CcSEcCtD
Maraviroc—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.000746	0.00117	CcSEcCtD
Maraviroc—Pain—Vincristine—lymphatic system cancer	0.000745	0.00117	CcSEcCtD
Maraviroc—Constipation—Vincristine—lymphatic system cancer	0.000745	0.00117	CcSEcCtD
Maraviroc—Pruritus—Bleomycin—lymphatic system cancer	0.000739	0.00116	CcSEcCtD
Maraviroc—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.000737	0.00116	CcSEcCtD
Maraviroc—Eosinophilia—Methotrexate—lymphatic system cancer	0.000736	0.00115	CcSEcCtD
Maraviroc—Fatigue—Mitoxantrone—lymphatic system cancer	0.000731	0.00115	CcSEcCtD
Maraviroc—Pancreatitis—Methotrexate—lymphatic system cancer	0.000728	0.00114	CcSEcCtD
Maraviroc—Pain—Mitoxantrone—lymphatic system cancer	0.000725	0.00114	CcSEcCtD
Maraviroc—Constipation—Mitoxantrone—lymphatic system cancer	0.000725	0.00114	CcSEcCtD
Maraviroc—Body temperature increased—Carmustine—lymphatic system cancer	0.000721	0.00113	CcSEcCtD
Maraviroc—Abdominal pain—Carmustine—lymphatic system cancer	0.000721	0.00113	CcSEcCtD
Maraviroc—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.000712	0.00112	CcSEcCtD
Maraviroc—Pancytopenia—Methotrexate—lymphatic system cancer	0.000705	0.00111	CcSEcCtD
Maraviroc—Neutropenia—Methotrexate—lymphatic system cancer	0.000695	0.00109	CcSEcCtD
Maraviroc—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.000693	0.00109	CcSEcCtD
Maraviroc—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00069	0.00108	CcSEcCtD
Maraviroc—Abdominal pain—Vincristine—lymphatic system cancer	0.000688	0.00108	CcSEcCtD
Maraviroc—Body temperature increased—Vincristine—lymphatic system cancer	0.000688	0.00108	CcSEcCtD
Maraviroc—Hypersensitivity—Carmustine—lymphatic system cancer	0.000672	0.00105	CcSEcCtD
Maraviroc—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00067	0.00105	CcSEcCtD
Maraviroc—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00067	0.00105	CcSEcCtD
Maraviroc—Pneumonia—Methotrexate—lymphatic system cancer	0.000666	0.00104	CcSEcCtD
Maraviroc—Vomiting—Bleomycin—lymphatic system cancer	0.000664	0.00104	CcSEcCtD
Maraviroc—Infestation NOS—Methotrexate—lymphatic system cancer	0.000662	0.00104	CcSEcCtD
Maraviroc—Infestation—Methotrexate—lymphatic system cancer	0.000662	0.00104	CcSEcCtD
Maraviroc—Depression—Methotrexate—lymphatic system cancer	0.00066	0.00103	CcSEcCtD
Maraviroc—Rash—Bleomycin—lymphatic system cancer	0.000659	0.00103	CcSEcCtD
Maraviroc—Dermatitis—Bleomycin—lymphatic system cancer	0.000658	0.00103	CcSEcCtD
Maraviroc—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	0.000657	0.00103	CcSEcCtD
Maraviroc—Asthenia—Carmustine—lymphatic system cancer	0.000654	0.00103	CcSEcCtD
Maraviroc—Renal failure—Methotrexate—lymphatic system cancer	0.000651	0.00102	CcSEcCtD
Maraviroc—Stomatitis—Methotrexate—lymphatic system cancer	0.000646	0.00101	CcSEcCtD
Maraviroc—Conjunctivitis—Methotrexate—lymphatic system cancer	0.000644	0.00101	CcSEcCtD
Maraviroc—Hypersensitivity—Vincristine—lymphatic system cancer	0.000641	0.00101	CcSEcCtD
Maraviroc—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.000626	0.000982	CcSEcCtD
Maraviroc—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.000625	0.000979	CcSEcCtD
Maraviroc—Asthenia—Vincristine—lymphatic system cancer	0.000625	0.000979	CcSEcCtD
Maraviroc—Diarrhoea—Carmustine—lymphatic system cancer	0.000624	0.000978	CcSEcCtD
Maraviroc—Nausea—Bleomycin—lymphatic system cancer	0.000621	0.000973	CcSEcCtD
Maraviroc—Agranulocytosis—Methotrexate—lymphatic system cancer	0.000618	0.000969	CcSEcCtD
Maraviroc—Asthenia—Mitoxantrone—lymphatic system cancer	0.000608	0.000953	CcSEcCtD
Maraviroc—Dizziness—Carmustine—lymphatic system cancer	0.000603	0.000945	CcSEcCtD
Maraviroc—Diarrhoea—Vincristine—lymphatic system cancer	0.000596	0.000933	CcSEcCtD
Maraviroc—Pharyngitis—Methotrexate—lymphatic system cancer	0.00059	0.000925	CcSEcCtD
Maraviroc—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.000587	0.00092	CcSEcCtD
Maraviroc—Urethral disorder—Methotrexate—lymphatic system cancer	0.000583	0.000913	CcSEcCtD
Maraviroc—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00058	0.000909	CcSEcCtD
Maraviroc—Vomiting—Carmustine—lymphatic system cancer	0.00058	0.000909	CcSEcCtD
Maraviroc—Dizziness—Vincristine—lymphatic system cancer	0.000576	0.000902	CcSEcCtD
Maraviroc—Rash—Carmustine—lymphatic system cancer	0.000575	0.000901	CcSEcCtD
Maraviroc—Dermatitis—Carmustine—lymphatic system cancer	0.000575	0.0009	CcSEcCtD
Maraviroc—Headache—Carmustine—lymphatic system cancer	0.000571	0.000895	CcSEcCtD
Maraviroc—Erythema multiforme—Methotrexate—lymphatic system cancer	0.000562	0.000881	CcSEcCtD
Maraviroc—Eye disorder—Methotrexate—lymphatic system cancer	0.000556	0.000871	CcSEcCtD
Maraviroc—Vomiting—Vincristine—lymphatic system cancer	0.000554	0.000867	CcSEcCtD
Maraviroc—Cardiac disorder—Methotrexate—lymphatic system cancer	0.000552	0.000865	CcSEcCtD
Maraviroc—Rash—Vincristine—lymphatic system cancer	0.000549	0.00086	CcSEcCtD
Maraviroc—Dermatitis—Vincristine—lymphatic system cancer	0.000548	0.000859	CcSEcCtD
Maraviroc—Headache—Vincristine—lymphatic system cancer	0.000545	0.000855	CcSEcCtD
Maraviroc—Nausea—Carmustine—lymphatic system cancer	0.000542	0.000849	CcSEcCtD
Maraviroc—Angiopathy—Methotrexate—lymphatic system cancer	0.000539	0.000845	CcSEcCtD
Maraviroc—Vomiting—Mitoxantrone—lymphatic system cancer	0.000539	0.000845	CcSEcCtD
Maraviroc—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.000536	0.00084	CcSEcCtD
Maraviroc—Rash—Mitoxantrone—lymphatic system cancer	0.000535	0.000838	CcSEcCtD
Maraviroc—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000534	0.000837	CcSEcCtD
Maraviroc—Headache—Mitoxantrone—lymphatic system cancer	0.000531	0.000832	CcSEcCtD
Maraviroc—Alopecia—Methotrexate—lymphatic system cancer	0.000525	0.000823	CcSEcCtD
Maraviroc—Mental disorder—Methotrexate—lymphatic system cancer	0.000521	0.000816	CcSEcCtD
Maraviroc—Malnutrition—Methotrexate—lymphatic system cancer	0.000518	0.000811	CcSEcCtD
Maraviroc—Erythema—Methotrexate—lymphatic system cancer	0.000518	0.000811	CcSEcCtD
Maraviroc—Nausea—Vincristine—lymphatic system cancer	0.000517	0.00081	CcSEcCtD
Maraviroc—Nausea—Mitoxantrone—lymphatic system cancer	0.000504	0.000789	CcSEcCtD
Maraviroc—Anaemia—Methotrexate—lymphatic system cancer	0.000478	0.00075	CcSEcCtD
Maraviroc—Leukopenia—Methotrexate—lymphatic system cancer	0.000463	0.000726	CcSEcCtD
Maraviroc—Cough—Methotrexate—lymphatic system cancer	0.000452	0.000708	CcSEcCtD
Maraviroc—Convulsion—Methotrexate—lymphatic system cancer	0.000448	0.000703	CcSEcCtD
Maraviroc—Myalgia—Methotrexate—lymphatic system cancer	0.000441	0.000691	CcSEcCtD
Maraviroc—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000438	0.000686	CcSEcCtD
Maraviroc—Discomfort—Methotrexate—lymphatic system cancer	0.000435	0.000682	CcSEcCtD
Maraviroc—Infection—Methotrexate—lymphatic system cancer	0.00042	0.000658	CcSEcCtD
Maraviroc—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000414	0.000649	CcSEcCtD
Maraviroc—Skin disorder—Methotrexate—lymphatic system cancer	0.00041	0.000643	CcSEcCtD
Maraviroc—Anorexia—Methotrexate—lymphatic system cancer	0.000403	0.000631	CcSEcCtD
Maraviroc—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000385	0.000603	CcSEcCtD
Maraviroc—Insomnia—Methotrexate—lymphatic system cancer	0.000382	0.000599	CcSEcCtD
Maraviroc—Paraesthesia—Methotrexate—lymphatic system cancer	0.000379	0.000594	CcSEcCtD
Maraviroc—Decreased appetite—Methotrexate—lymphatic system cancer	0.000367	0.000575	CcSEcCtD
Maraviroc—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000365	0.000572	CcSEcCtD
Maraviroc—Fatigue—Methotrexate—lymphatic system cancer	0.000364	0.000571	CcSEcCtD
Maraviroc—Pain—Methotrexate—lymphatic system cancer	0.000361	0.000566	CcSEcCtD
Maraviroc—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000345	0.000541	CcSEcCtD
Maraviroc—Abdominal pain—Methotrexate—lymphatic system cancer	0.000334	0.000523	CcSEcCtD
Maraviroc—Body temperature increased—Methotrexate—lymphatic system cancer	0.000334	0.000523	CcSEcCtD
Maraviroc—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000311	0.000488	CcSEcCtD
Maraviroc—Asthenia—Methotrexate—lymphatic system cancer	0.000303	0.000475	CcSEcCtD
Maraviroc—Pruritus—Methotrexate—lymphatic system cancer	0.000299	0.000468	CcSEcCtD
Maraviroc—Diarrhoea—Methotrexate—lymphatic system cancer	0.000289	0.000453	CcSEcCtD
Maraviroc—Dizziness—Methotrexate—lymphatic system cancer	0.000279	0.000438	CcSEcCtD
Maraviroc—Vomiting—Methotrexate—lymphatic system cancer	0.000269	0.000421	CcSEcCtD
Maraviroc—Rash—Methotrexate—lymphatic system cancer	0.000266	0.000417	CcSEcCtD
Maraviroc—Dermatitis—Methotrexate—lymphatic system cancer	0.000266	0.000417	CcSEcCtD
Maraviroc—Headache—Methotrexate—lymphatic system cancer	0.000265	0.000415	CcSEcCtD
Maraviroc—Nausea—Methotrexate—lymphatic system cancer	0.000251	0.000393	CcSEcCtD
